In­cyte's cash cow Jakafi chugs along with pos­i­tive front­line re­sults for GVHD

Five months af­ter the FDA ap­proved In­cyte to ex­pand its flag­ship Jakafi drug to pa­tients with steroid-re­frac­to­ry acute graft-ver­sus-host dis­ease (GVHD), the com­pa­ny an­nounced pos­i­tive topline re­sults from its Phase III study.

“This an­nounce­ment, while a pos­i­tive, is not sur­pris­ing giv­en the re­cent la­bel ex­pan­sion for Jakafi in the U.S. in­to this set­ting based on re­sults from the sin­gle-arm REACH1 tri­al,” Baird’s Bri­an Sko­r­ney wrote, adding that it should al­low No­var­tis, In­cyte’s part­ner, to be­gin reg­is­ter­ing the drug abroad.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER